Immutep (IMMP) Announces Publication of Abstracts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Immutep Announces Publication of Abstracts for ASCO 2023 Annual Meeting
May 26, 2023 8:00 AM EDTMedia Release
New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinomaDeep, durable responses seen across all PD-L1 subgroups with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months)In the overall patient population, regardless of PD-L1 expression, a strong response rate of 29.7% and 12-month... More